HSIC

Business Context and Reporting Period

Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 24, 2005
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners (dental, medical, veterinary) in North America and Europe. Operations are conducted through two segments: Healthcare Distribution and Technology.

Key Financial Metrics

(All figures in thousands, except per share data)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.3% for the quarter and 20.1% for the nine-month period compared to the prior year. Growth was driven by acquisitions (particularly in the International segment) and internal volume growth.
• Profitability: Operating income rose 20% for the quarter and 20.3% for the nine-month period. Gross margins improved across segments due to a focus on margin enhancement and shedding lower-margin products.
• Discontinued Operations: The company recorded a significant loss from discontinued operations ($9.95 million for the quarter; $10.31 million for nine months) related to the decision to divest its Hospital Supply Business. This included an $11.9 million impairment charge on long-lived assets.
• Acquisitions: Completed acquisitions of Ash Temple (Canada) and Austrodent (Austria), along with smaller acquisitions in Australia, New Zealand, and the U.S., contributing to revenue growth and goodwill increases.
• Expenses: Selling, general, and administrative (SG&A) expenses increased 17.1% for the quarter, primarily due to payroll and integration costs associated with recent acquisitions.

Guidance, Outlook, and Risks

• Divestiture: Management expects to sell the Hospital Business within 12 months. An additional loss upon sale is expected but cannot be reasonably estimated at this time.
• Capital Allocation: The company continues a share repurchase program. As of September 24, 2005, $63.4 million of a $100 million authorization had been used. On October 31, 2005, the Board authorized an additional $100 million for repurchases.
• Liquidity: The company maintains a $300 million revolving credit facility with no borrowings outstanding as of the period end. Management believes cash flows and credit facilities are sufficient for foreseeable needs.
• Risks: Key risks include industry consolidation, dependence on third-party suppliers, regulatory changes in healthcare (e.g., Medicare reform), foreign currency fluctuations, and the successful integration of acquired businesses.
• Accounting Changes: The company will adopt FAS 123(R) for stock-based compensation in the first quarter of 2006, which is expected to reduce reported net income by approximately the amount of the pro forma adjustments disclosed in the filing.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the final sale price and timing of the Hospital Business divestiture to assess the total financial impact beyond the initial $11.9 million impairment.
• Acquisition Integration: Monitor the integration progress of Ash Temple and Austrodent to ensure projected synergies and revenue growth are realized.
• Stock-Based Compensation: Review Q1 2006 results to confirm the impact of FAS 123(R) adoption on net income and EPS.
• Debt Structure: Note the $240 million convertible debt issued in 2004; monitor stock price levels relative to the conversion price ($46.34) to assess potential dilution or cash settlement obligations.
• Working Capital Trends: Track accounts receivable days sales outstanding (DSO) and inventory turnover, as these are critical for a distributor with high working capital requirements.